filings.toolsItem 16. FORM 10-K SUMMARY
4K characters. Original on sec.gov ·
Item 16. FORM 10-K SUMMARY
None.
SIGNATURES
Under the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.
| Pfizer Inc. | |||||||||||
| Dated: February 26, 2026 | By: | /S/ MARGARET M. MADDEN | |||||||||
| Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel |
We, the undersigned directors and officers of Pfizer Inc., hereby severally constitute Douglas M. Lankler and Margaret M. Madden, and each of them singly, our true and lawful attorneys with full power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Under the requirements of the Securities Exchange Act of 1934, this report was signed by the following persons on behalf of the Registrant and in the capacities and on the date indicated.
| Pfizer Inc. | 2025 Form 10-K | 111 |
| Signature | Title | Date | ||||||||||||
| /S/ ALBERT BOURLA Albert Bourla | Chairman, Chief Executive Officer and Director (Principal Executive Officer) | February 26, 2026 | ||||||||||||
| /S/ DAVID M. DENTON David M. Denton | Chief Financial Officer, Executive Vice President (Principal Financial Officer) | February 26, 2026 | ||||||||||||
| /S/ JENNIFER B. DAMICO Jennifer B. Damico | Senior Vice President and Controller (Principal Accounting Officer) | February 26, 2026 | ||||||||||||
| /S/ RONALD E. BLAYLOCK Ronald E. Blaylock | Director | February 26, 2026 | ||||||||||||
| /S/ MORTIMER J. BUCKLEY Mortimer J. Buckley | Director | February 26, 2026 | ||||||||||||
| /S/ SUSAN DESMOND-HELLMANN Susan Desmond-Hellmann | Director | February 26, 2026 | ||||||||||||
| /S/ JOSEPH J. ECHEVARRIA Joseph J. Echevarria | Director | February 26, 2026 | ||||||||||||
| /S/ SCOTT GOTTLIEB Scott Gottlieb | Director | February 26, 2026 | ||||||||||||
| /S/ SUSAN HOCKFIELD Susan Hockfield | Director | February 26, 2026 | ||||||||||||
| /S/ DAN R. LITTMAN Dan R. Littman | Director | February 26, 2026 | ||||||||||||
| /S/ SHANTANU NARAYEN Shantanu Narayen | Director | February 26, 2026 | ||||||||||||
| /S/ SUZANNE NORA JOHNSON Suzanne Nora Johnson | Director | February 26, 2026 | ||||||||||||
| /S/ JAMES QUINCEY James Quincey | Director | February 26, 2026 | ||||||||||||
| /S/ JAMES C. SMITH James C. Smith | Director | February 26, 2026 | ||||||||||||
| /S/ CYRUS TARAPOREVALA Cyrus Taraporevala | Director | February 26, 2026 |
| Pfizer Inc. | 2025 Form 10-K | 112 |
Previous: Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES